Autoantibodies and depression. Evidence for a causal link?

Neuroscience and Biobehavioral Reviews

Volumn 40, Issue , 2014, Pages 62-79

  Iseme, Rosebella Alungata ^a   McEvoy, Mark ^a,b   Kelly, Brian ^c,d   Agnew, Linda ^e   Attia, John ^a,b,f   Walker, Frederick Rohan ^c  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d NEWCASTLE MATER HOSPITAL   (Australia)

^e UNIVERSITY OF NEW ENGLAND   (Australia)

^f JOHN HUNTER HOSPITAL   (Australia)

Author keywords

Anti 5 HT autoantibodies; Anti endothelial cell autoantibodies; Anti ganglioside autoantibodies; Anti N methyl d aspartate receptor autoantibodies; Anti ds DNA autoantibodies; Anti gliadin autoantibodies; Anti nuclear autoantibodies; Anti P ribosomal autoantibodies; Anti phospholipid autoantibodies; Anti thyroid autoantibodies; Autoantibodies; Autoimmunity; Depression; Rheumatoid factor; Tissue transglutaminase autoantibodies

Indexed keywords

ANTI 5-HT AUTOANTIBODIES; ANTI ENDOTHELIAL CELL AUTOANTIBODIES; ANTI GANGLIOSIDE AUTOANTIBODIES; ANTI N-METHYL-D-ASPARTATE RECEPTOR AUTOANTIBODIES; ANTI-DS DNA AUTOANTIBODIES; ANTI-GLIADIN AUTOANTIBODIES; ANTI-NUCLEAR AUTOANTIBODIES; ANTI-P RIBOSOMAL AUTOANTIBODIES; ANTI-PHOSPHOLIPID AUTOANTIBODIES; ANTI-THYROID AUTOANTIBODIES; AUTOANTIBODIES; AUTOIMMUNITY; DEPRESSION; RHEUMATOID FACTOR; TISSUE TRANSGLUTAMINASE AUTOANTIBODIES;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; DEPRESSION; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOMODULATION;

EID: 84893767410     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2014.01.008     Document Type: Review

References (218)

1. Abbott N.J., Mendonça L.L., Dolman D.E. The blood-brain barrier in systemic lupus erythematosus. Lupus 2003, 12(12):908-915.
2. Alessandri C., Bombardieri M., Valesini G. Pathogenic mechanisms of anti-endothelial cell antibodies (AECA): their prevalence and clinical relevance. Advances in Clinical Chemistry 2006, 42:297-326.
3. Alexander J.J., Jacob A., Bao L., Macdonald R.L., Quigg R.J. Complement-dependent apoptosis and inflammatory gene changes in murine lupus ceribritis. Journal of Immunology 2005, 175(12):8312-8319.
4. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, Washington, DC. fourth ed.
5. Appleby B. Are anti-nuclear antibodies common in affective disorders? A review of the past 35 years. Psychosomatics 2007, 48(4):286-289.
6. Arinuma Y., Yanagida T., Hirohata S. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis and Rheumatism 2008, 58(4):1130-1135.
7. Armitage J.D., Homer-Vanniasinkam S., Lindsey N.J. The role of endothelial cell reactive antibodies in peripheral vascular disease. Autoimmunity Reviews 2004, 3(2):39-44.
8. Arnett F.C., Reveille J.D., Moutsopoulos H.M., Georgescu L., Elkon K.B. Ribosomal P autoantibodies in systemic lupus erythematosus. Frequencies in different ethnic groups and clinical and immunogenetic associations. Arthritis and Rheumatism 1996, 39(11):1833-1839.
9. Ballok D.A., Millward J.M., Sakic B. Neurodegeneration in autoimmune MRL-lpr mice as revealed by Fluro Jade B staining. Brain Research 2003, 964(2):200-210.
10. Ballermann B.J. Endothelial cell activation. Kidney International 1998, 53(6):1810-1826.
11. Bankier B., Barajas J., Martinez-Rumayor A., Januzzi J.L. Association between major depressive disorder and C-reactive protein levels in stable coronary heart disease patients. Journal of Psychosomatic Research 2009, 50(4):66189-66194.
12. Baune B.T., Dannlowski U., Domschke K., Janssen D.G.A., Jordan M.A., Ohrmann P., Bauer J., Biros E., Arott V., Kugel H., Baxter A.G., Suslow T. The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression. Biological Psychiatry 2010, 67(6):543-549.
13. Binder D.K., Scharfman H.E. Brain-derived neurotrophic factor. Growth Factors 2004, 22(3):123-131.
14. Blank M., Beinglass I., Shoenfeld Y. The therapeutic potential of targeting anti-Ribosomal-P antibody in treating SLE patients with depression. Expert Opinion on Biological Therapy 2007, 7(9):1283-1285.
15. Bonifati D.M., Kishore U. Role of complement in neurodegeneration and inflammation. Molecular Immunology 2007, 44(5):999-1010.
16. Brauchitsch V. Antinuclear factor in psychiatric disorders. American Journal of Psychiatry 1972, 128(12):1552-1554.
17. Bremner J.D. Does stress damage the brain?. Biological Psychiatry 1999, 45(7):797-805.
18. Brennan F.H., Anderson A.J., Taylor S.M., Woodruff T.M., Ruitenberg M.J. Complement activation in the injured central nervous system: another double-edged sword?. Journal of Neuroinflammation 2012, 9:137.
19. Bunevicius R., Kazanavicius G., Teksnys A. Thyrotrophin response to TRH stimulation in depressed patients with autoimmune thyroiditis. Biological Psychiatry 1994, 36(8):543-547.
20. Butterfield D.A., Opii W.O. Mitochondrial dysfunction in nervous system injury. University of Kentucky, Lexington, KY, USA 2009, 887-894. Elsevier Ltd.
21. Campbell S., MacQueen G. An update on regional brain volume differences associated with mood disorders. Current Opinion in Psychiatry 2006, 19(1):25-33.
22. Carta M.G., Hardoy M.C., Boi M.F., Mariotti S., Carpiniello B., Usai P. Association between panic disorder, major depressive disorder and celiac disease: a possible role of thyroid autoimmunity. Journal of Psychosomatic Research 2002, 53(3):789-793.
23. Carta M.G., Loviselli A., Hardoy M.C., Massa S., Cadeddu M., Sardu C., Carpiniello B., Dell'Osso L., Mariotti S. The link between thyroid autoimmunity (anti-thyroid peroxidase autoantibodies) with anxiety and mood disorders in the community: a field of interest for public health in the future. BMC Psychiatry 2004, 4:25.
24. Caruso C., Condore G., Cigna D., Colucci A.T., Modica M.A. Biological significance of soluble IL-2 receptor. Mediators of Inflammation 1993, 2(1):3-21.
25. Cerri A.P., Arosio B., Viazzoli C., Confalonieri R., Teruzzi F., Annoni G. 308(G/A) TNF-alpha gene polymorphism and risk of depression late in the life. Archives of Gerontology and Geriatrics 2009, 49(Suppl. 1):29-34.
26. Cerri A.P., Arosio B., Viazzoli C., Confalonieri R., Vergani C., Annoni G. The -308 (G/A) single nucleotide polymorphism in the TNF-α gene and the risk of major depression in the elderly. International Journal of Geriatric Psychiatry 2010, 25(3):219-223.
27. Chen P., Jiang T., Ouyang J., Chen Y. Depression, another autoimmune disease from the view of autoantibodies. Medical Hypothesis 2009, 73(4):508-509.
28. Chen Y., Jiang T., Chen P., Ouyang J., Xu G., Zeng Z., Sun Y. Emerging tendency towards autoimmune process in major depressive patients: a novel insight from Th17 cells. Psychiatry Research 2011, 188(2):224-230.
29. Clerici M., Arosio B., Mundo E., Cattaneo E., Pozzoli S., Dell'Osso B., Vergani C., Trabattoni D., Altamura A.C. Cytokine polymorphisms in the pathophysiology of mood disorders. CNS Spectrums 2009, 14(8):419-425.
30. Colasanti T., Delunardo F., Margutti P., Vacirca D., Piro E., Siracusano A., Ortona E. Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus. Journal of Neuroimmunology 2009, 212(1-2):3-9.
31. Conti .F., Alessandri C., Bompane D., Bombardieri M., Spinelli F.R., Rusconi A.C., Valesini G. Autoantibody profile in systemic lupus erythematosus with psychiatric manifestations: a role for anti-endothelial-cell antibodies. Arthritis Research and Therapy 2004, 6(4):R366-R372.
32. Costallat L.T., de Oliveira R.M., Santiago M.B., Cossermelli W., Samara A.M. Neuropsychiatric manifestations of systemic lupus erythematosus: the value of anticardiolipin, antigangliosides and antigalactocerebrosides antibodies. Clinical Rheumatology 1990, 9(4):489-497.
33. Cryan J.F., O'Mahony S.M. The microbiome-gut-brain axis: from bowel to behaviour. Neurogastroenterology & Motility 2011, 23(3):187-192.
34. Custro N., Scafidi V., Lo Baido R., Nastri L., Abbate G., Cuffaro M.P., Gallo S., Vienna G., Notarbartolo A. Subclinical hypothyroidism resulting from autoimmune thyroiditis in female patients with endogenous depression. Journal of Endocrinological Investigation 1994, 17(8):641-646.
35. Danner M., Kasl S.V., Abramson J.L., Vaccarino V. Association between depression and elevated C-reactive protein. Psychosomatic Medicine 2003, 65(3):347-356.
36. Deberdt R., van Hooren J., Amery W. Antinuclear factor a dysimmunological feature in mental depression. A preliminary conclusion. Psychotherapy and Psychosomatics 1974, 24(2):119-122.
37. Deberdt R., van Hooren J., Biesbrouk M., Amery W. Antinuclear factor positive in mental depression: a single entity?. Biological Psychiatry 1976, 11(1):69-74.
38. DeGiorgio L.A., Konstantinov K.N., Lee S.C., Hardin J.A., Volpe B.T., Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nature Medicine 2001, 7(11):1189-1193.
39. Deltheil T., Guiard B.P., Guilloux J.P., Nicolas L., Delomenie C., Reperant C., Le Maitre E., Leroux-Nicollet I., Benmansour S., Coudore F., David D.J., Gardier A.M. Consequences of changes in BDNF levels on serotonin neurotransmission, 5HT transporter expression and function: studies in adult mice hippocampus. Pharmacology, Biochemistry and Behaviour 2008, 90(2):174-183.
40. De Rivero Vaccari J.C., Corriveau R.A., Belousou A.B. Gap junctions are required for NMDA receptor dependent cell death in developing neurons. Journal of Neurophysiology 2007, 98(5):2878-2886.
41. Demartini B., Masu A., Scarone S., Pontiroli A.E., Gambini O. Prevalence of depression in patients affected by subclinical hypothyroidism. Panminerva Medica 2010, 52(4):277-282.
42. de Vries E., Schipperijn A.J.M., Breedveld F.C. Antinuclear antibodies in psychiatric patients. Acta Psychiatrica Scandinavica 1994, 89(4):289-290.
43. Diamond B. Antibodies and the brain: lessons from lupus. Journal of Immunology 2010, 185(5):2637-2640.
44. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., Lanctot K.L. A meta-analysis of cytokines in major depression. Biological Psychiatry 2010, 67(5):446-457.
45. Dunman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Archives of General Psychiatry 1997, 54(7):597-606.
46. Duval F., Mokrani M.C., Bailey P., Correa H., Diep T.S., Crocq M.A., Macher J.P. Thyroid axis activity and serotonin function in major depressive episode. Psychoneuroendocrinology 1999, 24(7):695-712.
47. Elhwuegi A.S. Central monoamines and their role in major depression. Progress in Neuro-psychopharmacology and Biological Psychiatry 2004, 28(3):435-451.
48. Eller T., Metsküla K., Talja I., Maron E., Uibo R., Vasar V. Thyroid autoimmunity and treatment response to escitalopram in major depression. Nordic Journal of Psychiatry 2010, 64(4):253-257.
49. Engum A., Bjøro T., Mykletun A., Dahl A.A. Thyroid autoimmunity, depression and anxiety; are there any connections? An epidemiological study of a large population. Journal of Psychosomatic Research 2005, 59(5):263-268.
50. Faust T.W., Chang E.H., Kowal C., Berlin R., Gazaryan I.G., Bertini E., Zhang J., Sanchez-Guerrero J., Fragoso-Loyo H.E., Volpe B.T., Diamond B., Huerta P.T. Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(43):18569-18574.
51. Fessel W.J. Disturbed serum proteins in chronic psychosis. Serological, medical and psychiatric correlations. Archives of General Psychiatry 1961, 4:154-159.
52. Fessel W.J. Macroglobin elevations in functional mental illness. Nature 1962, 193:1005.
53. Fetissov S.O., Dechelotte P. The new link between gut-brain axis and neuropsychiatric disorders. Current Opinion in Clinical Nutrition and Metabolic Care 2011, 14(5):477-482.
54. Fountoulakis K.N., Iacovides A., Grannaticos P., St Kaprinis G., Bech P. Thyroid function in clinical subtypes of major depression: an exploratory study. BMC Psychiatry 2004, 4:6.
55. Galecki P., Florkowski A., Bienkiewicz M., Szemraj J. Functional polymorphism of cyclooxygenase-2 gene (G-765C) in depressive patients. Neuropsychobiology 2010, 62(2):116-120.
56. Galeazzi M., Annunziata P., Sebastiani G.D., Bellisai F., Campanella V., Ferrara G.B., Font J., Houssiau F., Passiu G., De Ramon Garrido E., Fernandez-Nebro A., Bracci L., Scorza R., Puddu P., Jedryka-Goral A., Smolen J., Tincani A., Carcassi C., Morozzi G., Marcolongo R. Anti-ganglioside antibodies in a large cohort of European patients with systemic lupus erythematosus: clinical, serological, and HLA class II gene associations. European Concerted Action on the Immunogenetics of SLE. Journal of Rheumatology 2000, 27(1):135-141.
57. Gao H.X., Campbell S.R., Min-Hui C., Zong P., Hee Hwang J., Gulinello M., Putterman C. Depression is an early disease manifestation in lupus-prone MRL.lpr mice. Journal of Neuroimmunology 2009, 207(1-2):45-56.
58. Gao H.X., Sanders E., Tieng A.T., Putterman C. Sex and autoantibody titers determine the development of neuropsychiatric manifestations in lupus-prone mice?. Journal of Neuroimmunology 2010, 229(1-2):112-122.
59. Garcia F.D., Coquerel Q., do Rego J.-C., Cravezic A., Bole-Feysot C., Kiive E., Dechelotte P., Harro J., Fetissov S.O. Anti-neuropeptide Y plasma immunoglobulins in relation to mood and appetite in depressive disorder. Psychoneuroendocrinology 2012, 37(9):1457-1467.
60. Gatspar M., Muller W. Auto-antibodies in affective disorders. Progress in Neuro-Psychopharmacology 1981, 5(1):91-97.
61. Gerli R., Caponi L., Tincani A., Scorza R., Sabbadini M.G., Danieli M.G. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology 2002, 41(12):1357-1366.
62. Ghose K., Coppen A., Hurdle A.D.F., McIllroy I. Antinuclear antibodies, affective disorders and lithium therapy. Pharmakopsychiat 1977, 10(4):243-245.
63. Gleicher N. Postpartum depression, an autoimmune disease?. Autoimmunity Reviews 2007, 6(8):572-576.
64. Gold M.S., Pottas A.L., Extein I. Symptomless autoimmune thyroiditis in depression. Psychiatry Research 1982, 6(3):261-269.
65. Golombek S.J., Graus F., Elkon K.B. Auto antibodies in the cerebrospinal fluid of patients with systemic lupus erythematosus. Arthritis and Rheumatism 1986, 29(9):1090-1097.
66. Gono T., Kawaguchi Y., Kaneko H., Nishimura K., Hanaoka M., Kataoka S., Okamoto Y., Katsumata Y., Yamanaka H. Anti-NR2A antibody as a predictor for neuropsychiatric systemic lupus erythematosus. Rheumatology 2011, 50(9):1578-1585.
67. Gottfries C.G., Gottfries I. Antinuclear factors in relation to age, sex, mental disease and treatment with phenothiazine. Acta Psychiatrica Scandinavica 1974, 255:193-201.
68. Grotta L.J., Schachtman T.R., Moynihaan J.A., Cohen N., Ader R. Voluntary consumption of cyclophosphamide by MRL mice. Brain Behaviour and Immunity 1989, 3(3):263-273.
69. Haggerty J.J., Evans D.L., Golden R.N., Pedersen C.A., Simon J.S., Nemeroff C.B. The presence of antithyroid antibodies in patients with affective and nonaffective psychiatric disorders. Biological Psychiatry 1990, 27(1):51-60.
70. Haggerty J.J., Stern R.A., Mason G.A., Beckwith J., Morey C.E., Prange A.J. Subclinical hypothyroidism: a modifiable risk factor for depression?. American Journal of Psychiatry 1993, 150(3):508-510.
71. Haggerty J.J., Prange A.J. Borderline hypothyroidism and depression. Annual Review of Medicine 1995, 46:37-46.
72. Haggerty J.J., Silva S.G., Marquardt M., Mason G.A., Chang H.Y., Evans D.L., Golden R.N., Pedersen C. Prevalence of antithyroid antibodies in mood disorders. Depression and Anxiety 1997, 5(2):91-96.
73. Halestrap A.P., Clarke S.J., Javadov S.A. Mitochondrial permeability transition pore opening during myocardial reperfusion-a target for cardioprotection. Cardiovascular Research 2004, 61(3):372-385.
74. Hallert C. Psychiatric illness, gluten, and celiac disease. Biological Psychiatry 1982, 17(9):959-961.
75. Hardingham B.E., Bading H. The Yin and Yang of NMDA receptor signalling. Trends in Neurosciences 2003, 26(2):81-89.
76. Hardy C., Rosedale M., Messinger J.W., Kleinhaus K., Aujero N., Silva H., Goetz R.R., Goetz D., Harkavy-Friedman J., Malaspina D. Olfactory acuity is associated with mood and function in a pilot study of stable bipolar disorder patients. Bipolar Disorders 2012, 14(1):109-117.
77. Harlan J., Chen Y., Gubbins E., Mueller R., Roch J.M., Walter K., Lake M., Olsen T., Metzger P., Dorwin S., Ladror U., Egan D.A., Severin J., Johnson R.W., Holzman T.F., Voelp K., Davenport C., Beck A., Potter J., Gopalakrishnan M., Hahn A., Spear B.B., Halbert D.N., Sullivan J.P., Abkevich V., Neff C.D., Skolnick M.H., Shattuck D., Katz D.A. Variants in Apaf-1 segregating with major depression promote apoptosome function. Molecular Psychiatry 2006, 11(1):76-85.
78. Harris B., Fung H., Johns S., Kologlu M., Bhatti R., McGregor A.M., et al. Transient post-partum thyroid dysfunction and postnatal depression. Journal of Affective Disorders 1989, 17(3):243-249.
79. Harris B., Othman S., Davies J.A., Weppner G.J., Richards C.J., Newcombe R.G., Lazarus J.H., Parker A.B., Hall R., Philips D.I. Association between postpartum thyroid dysfunction and thyroid antibodies and depression. BMJ 1992, 305(6846):152-156.
80. Hart B.L. Behaviour of sick animals. The Veterinary clinics of North America. Food Animal Practice 1987, 3(2):383-391.
81. Hickie I., Bennett B., Mitchell P., Wilhelm K., Orlay W. Clinical and subclinical hypothyroidism in patients with chronic and treatment-resistant depression. Australian and New Zealand Journal of Psychiatry 1996, 30(2):246-252.
82. Hirano T., Miyajima H., Taniguchi O., Ueda A., Takai S., Hashimoto S., Hirose S., Okumura K. Anti asialo GM1 antibody detected in the patients' sera from systemic lupus erythematosus and Behcet's diseases with neurological manifestations. Japanese Journal of Medicine 1988, 27(2):167-171.
83. Hirohata S., Arinuma Y., Takayama M., Yoshio T. Association of cerebrospinal fluid anti-ribosomal p protein antibodies with diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus. Arthritis Research & Therapy 2007, 9(3):R44.
84. Ho R.C., Fu E.H., Chua A.N., Cheak A.A., Mak A. Clinical and psychosocial factors associated with depression and anxiety in Singaporean patients with rheumatoid arthritis. International Journal of Rheumatic Diseases 2011, 14(1):37-47.
85. Holtzheimer P.E, Nemeroff C.B. Future prospects in depression research. Dialogues in Clinical Neurosciences 2006, 8(2):175-189.
86. Hong C.J., Yu Y.W.Y., Chen T.J., Tsai S.J. Interleukin-6 genetic polymorphism and Chinese major depression. Neuropsychobiology 2005, 52(4):202-205.
87. Hornig M., Amsterdam J.D., Kamoun M., Goodman D.B. Autoantibody disturbances in affective disorders: a function of age and gender?. Journal of Affective Disorders 1999, 55(1):29-37.
88. Horkko S., Miller E., Dudi E., Reaven P., Curtis K.L., Zvaifler J.N., Terkeltaub R., Pierangeli S.S., Branch W.D., Palinski W., Witztum J.L. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of low density lipoprotein. Journal of Clinical Investigation 1996, 98(3):815-825.
89. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosomatic Medicine 2009, 71(2):171-186.
90. Huerta P.T., Kowal C., DeGiorgio L.A., Volpe B.T., Diamond B. Immunity and behaviour: antibodies alter emotion. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(3):678-683.
91. Hwang J.P., Tsai S.J., Hong C.J., Yang C.H., Hsu C.D., Liou Y.J. Interleukin-1 beta -511C/T genetic polymorphism is associated with age of onset of geriatric depression. Neuromolecular Medicine 2009, 11(4):322-327.
92. Joffe R.T. Antithyroid antibodies in major depression. Acta Psychitrica Scandinavica 1987, 76(5):598-599.
93. Joffe R.T., Levitt A.J. Major depression and subclinical (grade 2) hypothyroidism?. Psychoneuroendocrinology 1992, 17(2-3):215-221.
94. Johnstone E.C., Whaley K. Antinuclear antibodies in psychiatric illness: their relationship to diagnosis and drug treatment. BMJ 1975, 2(5973):724-725.
95. Kato H., Yamathawa M., Ogino T. Complement mediated vascular endothelial injury in rheumatoid nodules: a histopathological and immunohistochemical study. Journal of Rheumatology 2000, 27(8):1839-1847.
96. Katzav A., Solodeev I., Brodsky O., Chapman J., Pick C.G., Blank M., Zhang W., Reichlin M., Shoenfeld Y. Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. Arthritis and Rheumatism 2007, 56(3):938-948.
97. Katzav A., Ben-Ziv T., Chapman J., Blank M., Reichlin M., Shoenfeld Y. Anti-P ribosomal antibodies induce defect in smell capability in a model of CNS-SLE (depression). Journal of Autoimmunity 2008, 31(4):393-398.
98. Kelly J.P., Wrynn A.S., Leonard B.E. The olfactory bulbectomised rat as a model of depression: an update. Pharmacology & Therapeutics 1997, 74(3):299-316.
99. Kent S., Bluthe R.M., Dantzer R., Hardwick A.J., Kelley K.W., Rothwell N.J., Vannice J.L. Different receptor mechanisms mediate the pyrogenic and behavioural effects of interleukin 1. Proceedings of the National Academy of Sciences of the United States of America 1992, 89(19):9117-9120.
100. Kollmeier A., Kreditor M., George J., Levy V., Shoenfeld Y. Functional properties of antiendothelial cell antibodies. Clinical Reviews in Allergy & Immunology 1998, 16(3):297-302.
101. Koolschijn P.C.M.P., Van Haren N.E.M., Lensvelt-Mulders G.J.L.M., Hulshoff Pol H.E., Kahn R.S. Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Human Brain Mapping 2009, 30(11):3719-3735.
102. Kowal C., DeGiorgio L.A., Lee J.Y., Edgar M.A., Huerta P.T., Volpe B.T., Diamond B. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(52):19854-19859.
103. Kozora E., West S.G., Maier S.F., Filley C.M., Arciniegas D.B., Brown M., Miller D., Grimm A., Zhang L. Antibodies against N-methyl-d-aspartate receptors in patients with systemic lupus erythematosus without neuropsychiatric syndromes?. Journal of the Neurological Sciences 2010, 295(1-2):87-91.
104. Kugaya A., Sanacora G. Beyond monoamines: glutamatergic function in mood disorders. CNS Spectrums 2005, 10(10):808-819.
105. Kuijpens J.L., Vader H.L., Drexhage H.A., Wiersinga W.M., Van Son M.J., Pop V.J. Thyroid peroxidase antibodies during gestation are a marker for subsequent depression postpartum. European Journal of Endocrinology/European Federation of Endocrine Societies 2001, 145(5):579-584.
106. Lapteva L., Nowak M., Yarboro C.H., Takada K., Roebuck-Spencer T., Weickert T., Bleiberg J., Rosenstein D., Pao M., Patronas N., Steele S., Manzano M., van der Veen J.W., Lipsky P.E., Marenco S., Wesley R., Volpe B., Diamond B., Illei G.G. Anti N-methyl-d-aspartate receptor antibodies, cognitive dysfunction and depression in systemic lupus erythematosus. Arthritis and Rheumatism 2006, 54(8):2505-2514.
107. Laske C., Zank M., Klein R., Stransky E., Batra A., Buchkremer G., Schott K. Autoantibody reactivity in serum of patients with major depression, schizophrenia and healthy controls. Psychiatry Research 2008, 158(1):83-86.
108. Lawrence D.A., Bolivar V.J., Hudson C.A., Mondal T.K., Pabello N.G. Antibody induction of lupus-like neuropsychiatric manifestations?. Journal of Neuroimmunology 2007, 182(1-2):185-194.
109. Le Donne M., Settineri S., Benvenga S. Early postpartum alexithymia and risk for depression: relationship with serum thyrotrophin, free thyroid hormones and thyroid autoantibodies. Psychoneuroendocrinology 2012, 37(4):519-533.
110. Legros S., Mendelwicz J., Wybran J. Immunoglobulins, autoantibodies and other serum protein fractions in psychiatric disorders. European Archives of Psychiatry and Neurological Sciences 1985, 235(1):9-11.
111. Liu Y., Ho R.C.M., Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. Journal of Affective Disorders 2012, 139(3):230-239.
112. Ludvigson J.F., Reutfors J., Osby U., Ekbom A., Montgomery S.M. Coeliac disease and risk of mood disorders - a general population-based cohort study?. Journal of Affective Disorders 2007, 99(1-3):117-126.
113. MacQueen G.M., Campbell S., McEwen B.S., Macdonald K., Amano S., Joffe R.T., Nahmias C., Young L.T. Course of illness, hippocampal function, and hippocampal volume in major depression. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(3):1387-1392.
114. Maes M., Bosmans E., Suy E., Vandervorst C., De Jonckheere C., Raus J. Immune disturbances during major depression: upregulated expression of interleukin-2 receptors. Neuropsychobiology 1990-91, 24(3):115-120.
115. Maes M., Bosmans E., Suy E., Vandervorst C., Dejonckheere C., Raus J. Antiphospholipid, antinuclear, Epstein-Barr and cytomegalovirus antibodies and soluble interleukin-2-receptors in depressive patients. Journal of Affective Disorders 1991, 21(2):133-140.
116. Maes M., Stevens W.J., DeClerck L.S., Bridts C.H., Peeters D., Schotte C., Cosyns P. A significantly increased number and percentage of B cells in depressed subjects: results of flow cytometric measurements. Journal of Affective Disorders 1992, 24(3):127-134.
117. Maes M., Stevens W., DeClerk L., Bridts C., Peeters D., Schotte C., Cosyns P. Immune disorders in depression: higher T helper/T suppressor-cytotoxic cell ratio. Acta Psychiatrica Scandinavica 1992, 86(6):423-431.
118. Maes M., Meltzer H., Jacobs J., Suy E., Calabrese J., Minner B., Raus J. Autoimmunity in depression: increased antiphospholipid autoantibodies. Acta Psychiatrica Scandinavica 1993, 87(3):160-166.
119. Maes M. A review on the acute phase response in major depression. Reviews in the Neurosciences 1993, 4(4):407-416.
120. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Progress in Neuropsychopharmacology and Biological Psychiatry 1995, 19(1):11-38.
121. Maes M., Meltzer H.Y., Bosmans E., Bergmans R., Vandoolaeghe E., Raujan R., Desnyder R. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. Journal of Affective Disorders 1995, 34(4):301-309.
122. Maes M., Yirmyia R., Noraberg J., Brene S., Hibbeln J., Perini G., Kubera M., Bob P., Lerer B., Maj M. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metabolic Brain Disease 2009, 24(1):27-53.
123. Maes M., Leonard B., Fernandez A., Kubera M., Nowak G., Veerhuis R., Gardner A., Ruckoanich P., Geffard M., Altamura C., Galecki P., Berk M. (Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: from antioxidants to kinase inhibitors. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2011, 35(3):659-663.
124. Maes M., Mihaylova I., Leunis J.C. Increased serum IgM antibodies directed against phosphatidyl inositol (Pi) in chronic fatigue syndrome (CFS) and major depression: evidence that an IgM-mediated immune response against Pi is one factor underpinning the comorbidity between both CFS and depression. Neuroendocrinology Letters 2007, 28(6):861-867.
125. Maes M., Mihaylova I., Ategis J.C. Evidence for an IgM-mediated immune response directed against nitrobovine serum albumins (BSA) in chronic fatigue syndrome (CFS) and major depression (MDD): evidence that an immune response to nitrosative stress-induced damage of BSA is more pronounced in CFS than in MDD. Neuroendocrinology Letters 2008, 29(3):313-319.
126. Maes M., Mihaylova I., Kubera M., Uytterhoeven M., Vrydags N., Bosmans E. Increased plasma peroxides and serum oxidised low density lipoprotein antibodies in major depression: markers that further explain the higher incidence of neurodegeneration and coronary artery disease?. Journal of Affective Disorders 2010, 125(1-3):287-294.
127. Maes M., Meltzer H.Y., Scharpe S., Bosmans E., Bergmans R., Desnyder R. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro) degenerative processes in that illness. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2011, 35(3):676-692.
128. Maes M., Mihaylova I., Kubera M., Leunis J.C., Geffard M. IgM-mediated autoimmune responses directed against multiple neoepitopes in depression: new pathways that underpin the inflammatory and neuroprogressive pathophysiology?. Journal of Affective Disorders 2012, 135(1-3):414-418.
129. Mathsson L., Lampa J., Mullazehi M., Ronnelid J. Immune complexes from rheumatoid arthritis synovial fluid induce FcγRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-α by peripheral blood mononuclear cells. Arthritis Research & Therapy 2006, 8(R64):1-10.
130. Matthews K.A., Schott L.L., Bromberger J.T., Cyranowski J.M., Everson-Rose S.A., Sowers M. Are there bi-directional associations between depressive symptoms and C-reactive protein in mid-life women?. Brain, Behavior, and Immunity 2010, 24(1):96-101.
131. Meroni P.L., Tincani A., Sepp N., Raschi E., Testoni C., Corsini E., Cavazzana I., Pellegrini S., Salmaggi A. Endothelium and the brain in CNS lupus. Lupus 2003, 12(12):919-928.
132. McCoy S.J.B., Beal J.M., Payton M.E., Stewart A.L., DeMers A.M., Watson G.H. Postpartum thyroid measures and depressive symptomology: a pilot study. Journal of the American Osteopathic Association 2008, 108(9):503-507.
133. McDonald E.M., Mann A.H., Thomas H.C. Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers. Lancet 1987, 2(8569):1175-1178.
134. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biological Psychiatry 2009, 65(9):732-741.
135. Min W., Liu C., Yang Y., Sun X., Zhang B., Xu L., Sun X. Alterations in hypothalamic-pituitary-adrenal/thyroid (HPA/HPT) axes correlated with the clinical manifestations of depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2012, 39(1):206-211.
136. Mondal T.K., Saha S.K., Miller V.M., Seegal R.F., Lawrence D.A. Autoantibody-mediated neuroinflammation: pathogenesis of neuropsychiatric systemic lupus erythematosus in the NZM88 murine model. Brain, Behavior, and Immunity 2008, 22(6):949-959.
137. Müller M.B., Lucassen P.J., Yassouridis A., Hoogendijk W.J., Holsboer F., Swaab D.F. Neither major depression nor glucocorticoid treatment affects the cellular integrity of the human hippocampus. European Journal of Neuroscience 2001, 14(10):1603-1612.
138. Muller N., Schwarz M.J. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Molecular Psychiatry 2007, 12(11):988-1000.
139. Nagai T., Arinuma Y., Yanagida K., Yamamoto K., Hirohata S. Anti-ribosomal protein antibody in human systemic lupus erythematosus up-regulates the expression of proinflammatory cytokines by human peripheral monocytes. Arthritis and Rheumatism 2005, 52(3):847-855.
140. Nauta A.J., Daha M.R., Tijsma O., van de Water B., Tedesco F., Roos A. The membrane attack complex of complement induces caspase activation and apoptosis. European Journal of Immunology 2002, 32(3):783-792.
141. Nauta A.J., Daha M.R., van Kooten C., Roo A. Recognition and clearance of apoptotic cells: a role for complement and pentraxins. Trends in Imuunology 2003, 24(3):148-154.
142. Negoias S., Croy I., Gerber J., Puschmann S., Petrowski K., Joraschky P., Hummel T. Reduced olfactory bulb volume and olfactory sensitivity in patients with acute major depression. Neuroscience 2010, 169(1):415-421.
143. Nemeroff C.B., Simon J.S., Haggerty J.J., Evans D.L. Antithyroid antibodies in depressed patients. American Journal of Psychiatry 1985, 142(7):840-843.
144. Nery F.G., Borba E.F., Viana V.S., Hatch J.P., Soares J.C., Bonfá E., Neto F.L. Prevalence of depressive and anxiety disorders in systemic lupus erythematosus and their association with anti-ribosomal P antibodies. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008, 32(3):695-700.
145. Nibuya M., Morinobu S., Duman R.S. Regulation of BDNF and trκB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. Journal of Neuroscience 1995, 15(11):7539-7547.
146. Nibuya M., Nestler E.J., Duman R.S. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. Journal of Neuroscience 1996, 16(7):2365-2372.
147. Niiranen A., Laaksonen R., Iivanainen M., Mattson K., Farkkila M., Cantell K. Behavioural assessment of patients treated with alpha-interferon. Acta Psychiatrica Scandinavica 1988, 78(5):622-626.
148. Nojima Y., Minota S., Yamada A., Takaku F., Aotsuka S., Yokohari R. Correlation of antibodies to ribosomal P protein with psychosis in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases 1992, 51(9):1053-1055.
149. Omdal R., Brokstad K., Waterloo K., Koldingsnes W., Jonsson R., Mellgren S.I. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. European Journal of Neurology 2005, 12(5):392-398.
150. Oreskes I., Rosenblatt S., Spiera H., Meadow H. Rheumatoid factors in an acute psychiatric population. Annals of the Rheumatic Diseases 1968, 27(1):60-63.
151. Palagini L., Mosca M., Tani C., Gemignani A., Mauri M., Bombardieri S. Depression and systemic lupus erythematosus: a systematic review. Lupus 2012, 22(5):409-416.
152. Palucha A., Pilc A. The involvement of glutamate in the pathophysiology of depression. Drug News & Perspectives 2005, 18(4):262-268.
153. Pikhart H., Hubacek J.A., Kubinova R., Nicholson A., Peasey A., Capkova N., Poledne R., Bobak M. Depressive symptoms and levels of C-reactive protein: a population based study. Social Psychiatry and Psychiatric Epidemiology 2009, 44(3):217-222.
154. Pop V.J., de Rooy H.A., Vader H.L., van der Heide D., van Son M., Komproe I.H., Essed G.G.M., de Geus C.A. Postpartum thyroid dysfunction and depression in an unselected population. New England Journal of Medicine 1991, 324(25):1815-1816.
155. Pop V.J.M., De Rooy H.A.M., Vade H.L., Van Der Heide D., Van son M.M., Komproe I.H. Microsomal antibodies during gestation in relation to postpartum thyroid dysfunction and depression. Acta Endocrinology 1993, 129(1):26-30.
156. Pop V.J., Maartens L.H., Leusink G., van Son M.J., Knottnerus A.A., Ward A.M., Metcalfe R., Weetman A.P. Are autoimmune thyroid dysfunction and depression related?. Journal of Clinical Endocrinology and Metabolism 1998, 83(9):3194-3197.
157. Rajkowska G. Cell pathology in mood disorders. Seminars in Clinical Neuropsychiatry 2002, 7(4):281-292.
158. Reichenberg A., Yirmiya R., Schuld A., Kraus T., Haack M., Morag A., Pollmacher T. Cytokine-associated emotional and cognitive disturbances in humans. Archives of General Psychiatry 2001, 58(5):445-452.
159. Roitt I.M. Chapter 1. Prevailing theories in autoimmune disorders. Ciclosporin in Autoimmune Diseases 1985, 5-15. Springer, Berlin, Heidelberg. R. Schindler (Ed.).
160. Roos R.P., Davis K., Meltzer H.Y. Immunoglobulin studies in patients with psychiatric diseases. Archives of General Psychiatry 1985, 42(4):124-128.
161. Rose N.R. Pathogenic mechanisms in autoimmune diseases. Clinical Immunology and Immunopathology 1989, 53(2):S7-S16.
162. Rosenblatt S., Oreskes I., Meadow H., Spiera H. The relationship between antigammaglobulin activity and depression. American Journal of Psychiatry 1968, 124(12):1640-1644.
163. Roy B.F., Bowen W.D., Frazier J.S., Rose J.W., McFarland H.F., McFarlin D.E., Murphy D.L., Morihisa J.M. Human antiidiotypic antibody against opiate receptors. Annals of Neurology 1988, 24(1):57-63.
164. Ruuskanen A., Kaukinen K., Collin P., Huhtala H., Valve R., Mäki M., Luostarinen L. Positive serum antigliadin antibodies without celiac disease in the elderly population: does it matter?. Scandinavian Journal of Gastroenterology 2010, 45(10):1197-1202.
165. Saadi S., Platt J.L. Transient perturbation of endothelial integrity induced by natural antibodies and complement. Journal of Experimental Medicine 1995, 181(1):21-31.
166. Sakić B., Szechtman H., Talangbayan H., Denburg S.D., Carbotte R.M., Denburg J.A. Disturbed emotionality in autoimmune MRL-lpr mice. Physiology and Behavior 1994, 56(3):609-617.
167. Sakic B., Szechtman H., Denburg S.D., Denburg J.A. Immunosuppressive treatment prevents behavioural deficit in autoimmune MRL-lpr mice. Physiology and Behavior 1995, 58(4):797-802.
168. Sakic B., Denburg J.A., Denburg S.D., Szechtman H. Blunted sensitivity to sucrose reward in autoimmune MRL-lpr mice: a curve shift study. Brain Research Bulletin 1996, 41(5):305-311.
169. Sakić B., Szechtman H., Denburg J.A. Neurobehavioural alterations in autoimmune mice. Neuroscience & Biobehavioral Reviews 1997, 21(3):327-340.
170. Sakic B., Kolb B., Whishaw I.Q., Gonry G., Szechtman H., Denburg J.A. Immunosuppression prevents neuronal atrophy in lupus prone mice: evidence for brain damage induced by autoimmune disease?. Journal of Neuroimmunology 2000, 111(1-2):93-101.
171. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Duwala S., Weisstaub N., Lee J., Duman R., Arancio O., Betzung C., Hen R. Requirement of hippocampal neurogenesis for the behavioural effects of antidepressants. Science 2003, 301(5634):805-809.
172. Santer D.M., Yoshio T., Minota S., Moller T., Elkon K.B. Potent induction of IFN-α and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus. Journal of Immunology 2009, 182(2):1192-1202.
173. Sato T., Uchiumi T., Ozawa T., Kikuchi M., Nakano M., Kominami R., Arakawa M. Autoantibodies against ribosomal proteins found with high frequency in patients with systemic lupus erythematosus with active disease. Journal of Rheumatology 1991, 18(11):1681-1684.
174. Schneebaum A.B., Singleton J.D., West S.G., Blodgett J.K., Allen L.G., Cheronis J.C., Kotzin B.L. Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. American Journal of Medicine 1991, 90(1):54-62.
175. Schott K., Uhl A., Batra A., Bartels M., Eusterschulte B., Buchkremer G. Antinuclear antibodies in schizophrenia and major depressive disorder - a lasting puzzle. European Psychiatry 1996, 11(5):263-267.
176. Schott K., Schaefer J.E., Richartz E., Batra A., Eusterschulte B., Klein R., Berg P.A., Bartels M., Mann K., Bluchkremer G. Autoantibodies against serotonin in serum of patients with psychiatric disorders. Psychiatry Research 2003, 121(1):51-57.
177. Schwartz M.M., Roberts J.L. Membranous and vascular choroidopathy: two patterns of immune deposits in systemic lupus erythematosus. Clinical Immunology and Immunopathology 1983, 29(3):369-380.
178. Sheline Y.I., Wang P.W., Gado M.H., Csernasky J.G., Vannier M.W. Hippocampal atrophy in recurrent major depression. Proceedings of the National Academy of Sciences of the United States of America 1996, 93(9):3908-3913.
179. Shelton R.C., Claiborne J., Sidoryk-Wegrzynowicz M., Reddy R., Aschner M., Lewis D.A., Mirnics K. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Molecular Psychiatry 2011, 16(7):751-762.
180. Sherer Y., Gorstein A., Fritzler M.J., Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 10 different antibodies found in SLE patients. Seminars in Arthritis and Rheumatism 2004, 34(2):501-537.
181. Shoenfeld D., Turk J.L., Isenberg Y. The Mosaic of Autoimmunity: The Factors Associated With Autoimmune Disease, No. 12 1989, Elsevier Science Ltd., UK.
182. Shoenfeld Y. To smell autoimmunity: anti-P-ribosomal autoantibodies, depression, and the olfactory system. Journal of Autoimmunity 2007, 28(2-3):165-169.
183. Shopsin B., Sathananthan G.L., Chan T.L., Kravitz H., Gershon S. Antinuclear factor in psychiatric patients. Biological Psychiatry 1973, 7(2):81-87.
184. Sibley J.T., Olszynski W.P., Decoteau W.E., Sundaram M.B. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. Journal of Rheumatology 1992, 19(1):47-52.
185. Sluzewska A., Rybakowski J., Bosmans E., Sobieski M., Berghmans R., Maes M., Wiktorowicz K. Indicators of immune activation in major depression. Psychiatry Research 1996, 64(3):161-167.
186. Smith R.S. The macrophage theory of depression. Medical Hypotheses 1991, 35(4):298-306.
187. Soledad M., Burgos P.V., Bravo-Zehnder M., Kraft R., Omar H., Porras O.H., Farías P., Barros L.F., Torrealba F., Massardo L., Jacobelli S., González A. Antiribosomal-P autoantibodies from psychiatric lupus target a novel neuronal surface protein causing calcium influx and apoptosis. Journal of Experimental Medicine 2007, 204(13):3221-3234.
188. Song Y.W., Kang E.H. Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies. Quarterly Journal of Medicine 2010, 103(3):139-146.
189. Sontheimer R.D., Racila E., Racila D.M. C1q: its functions within the innate and adaptive immune responses and its role in lupus autoimmunity. Journal of Investigative Dermatology 2005, 125(1):14-23.
190. Spriggs D.R., Sherman M.L., Michie H., Arthur K.A., Imamura K., Wilmore D., Frei E., Kufe D.W. Recombinant human tumour necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. Journal of the National Cancer Institute 1988, 80(13):1039-1044.
191. Stanojcic M., Loheswaran G., Xu L., Hoffman S.A., Sakic B. Intrathecal antibodies and brain damage in autoimmune MRL mice. Brain, Behavior, and Immunity 2010, 24(2):289-297.
192. Stewart J.C., Rand K.L., Muldoon M.F., Kamarck T.W. A prospective evaluation of the directionality of the depression inflammation relationship. Brain, Behavior, and Immunity 2009, 23(7):936-944.
193. Stockmeieir C.A., Mahajan G.J., Konick L.C., Overholser J.C., Jurjus G.J., Meltzer H.Y., Uylings H.B., Friedman L., Rajkowska G. Cellular changes in the postmortem hippocampus in major depression. Biological Psychiatry 2004, 56(9):640-650.
194. Strous R., Shoenfeld Y. Behavioral changes in systemic lupus erythematosus are of an autoimmune nature. Nature Clinical Practice Rheumatology 2007, 3(11):592-593.
195. Szapacs M.E., Mathews T.A., Tessarollo L., Lyons W.E., Mamounas L.A., Andrews A.M. Exploring the relationship between serotonin and brain derived neurotrophic factor: analysis of BDNF protein and extraneuronal 5HT in mice with reduced serotonin transporter or BDNF expression?. Journal of Neuroscience 2004, 140(1-2):81-92.
196. Tanaka S., Matsunaga H., Kimura M., Tatsumi Ki Hidaka Y., Takano T., Uema T., Takeda M., Amino N. Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders?. Journal of Neuroimmunology 2003, 141(1-2):155-164.
197. Tuckova L., Karska K., Walters J.R., Michalak M., Rossman P., Krupickova S., Verdu E.F., Saalman R., Hanson L.A., Tlaskalova-Hogenova H. Antigliadin antibodies in patients with celiac disease cross react with enterocytes and human calreticulin. Clinical Immunology and Immunopathology 1997, 85(3):289-296.
198. Tynan R.J., Beynon J.B., Hinwood M., Johnson S.J., Nilsson M., Woods J.J., Walker F.R. Chronic stress induced disruption of the astrocyte network is driven by structural atrophy and not loss of astrocytes. Acta Neuropathologica 2013, 126(1):75-91.
199. Tzioufas A.G., Tzortzakis N.G., Panou-Pomonis E., Boki K.A., Sakarellos-Daitsiotis M., Sakarellos C., Moutsopoulos H.M. The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: a large cohort of consecutive patients and patients with active central nervous system disease. Annals of the Rheumatic Diseases 2000, 59(2):99-104.
200. Utset T.O., Golden M., Siberry G., Kiri N., Crum R.M., Petri M. Depressive symptoms in patients with systemic lupus erythematosus: association with central nervous system lupus and Sjögren's syndrome. Journal of Rheumatology 1994, 21(11):2039-2045.
201. Valesini G., Alessandri C., Celestino D., Conti F. Anti-endothelial antibodies and neuropsychiatric systemic lupus erythematosus. Annals of the New York Academy of Sciences 2006, 1069:118-128.
202. Videbech P., Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. American Journal of Psychiatry 2004, 161(11):1957-1966.
203. Villemain F., Magnin M., Feuillet-Fieux M.N., Bach J.F., Zarifian E., Loo H. Anti-histone antibodies in schizophrenia and affective disorders. Psychiatry Research 1988, 24(1):53-60.
204. Volpe B.T. Delayed neuronal degeneration results from endogenous glutamate excess. Possible role in NP-SLE. Annals of the New York Academy of Sciences 1997, 823:185-187.
205. Wager-Smith K., Markou A. Depression: a repair response to stress-induced neuronal microdamage that can grade into a chronic neuroinflammatory condition?. Neuroscience and Biobehavioral Reviews 2011, 35(3):742-764.
206. Walker F.R. A critical review of the mechanism of action for the selective serotonin reuptake inhibitors: do these drugs possess anti-inflammatory properties and how relevant is this in the treatment of depression?. Neuropharmacology 2013, 67:304-317.
207. Waxman E.A., Lynch D.R. N-methyl-d-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease. Neuroscientist 2005, 11(1):37-49.
208. William S., Sakic B., Hoffman S.A. Circulating brain-reactive autoantibodies and behavioural deficits in MRL model of CNS lupus. Journal of Neuroimmunology 2010, 218(1-2):73-82.
209. Wong M.L., Dong C., Maestre-Mesa J., Licinio J. Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. Molecular Psychiatry 2008, 13(8):800-812.
210. World Health Organisation Depression Factsheet 2012, October, www.who.int/mediacentre/factsheets/fs369/en/ (accessed 16.05.12).
211. Yirmiya R. Endotoxin produces a depressive-like episode in rats. Brain Research 1996, 711(1-2):163-174.
212. Yimriya R., Pollak Y., Morag M., Reichenberg A., Barak O., Avitsur R., Shavit Y., Ovadia H., Jveidenfeld J., Morag A., Newman M.E., Pollmacher T. Illness, cytokines and depression. Annals of the New York Academy of Sciences 2000, 917:478-487.
213. 2+ deficiency. Journal of Neurochemistry 2003, 85(2):525-533.
214. Yoshio T., Masuyana J., Misota S., Iwamoto M., Mimori A., Takeda A., Okazaki H., Kano S. Correlation of serum IgG antibodies to carboxyl-terminal 22 synthetic peptides and carboxyl-terminal 22 amino acid-depleted recombinant P0 fusion protein in patients with systemic lupus erythematosus. Arthritis and Rheumatism 1997, 40(7):1364-1365.
215. Yoshio T., Hirohata D., Onda K., Nara H., Minota S. Antiribosomal P protein antibodies in cerebrospinal fluid are associated with neuropsychiatric systemic lupus erythematosus. Journal of Rheumatology 2005, 32(1):34-39.
216. Yoshio T., Onda K., Nara H., Minota S. Association of IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid with neuropsychiatric systemic lupus erythematosus. Arthritis and Rheumatism 2006, 54(2):675-678.
217. Zameer A., Hoffman S.A. Increased ICAM-1 and VCAM-1 expression in the brains of autoimmune mice?. Journal of Neuroimmunology 2003, 142(1-2):67-74.
218. Zameer A., Hoffman S.A. B and T cells in brains of autoimmune mice?. Journal of Neuroimmunology 2004, 146(1-2):133-139.